Business
Rivian R3X
CEO “RJ” Scaringe speaks at the launch of the Rivian R3X (Patrick T. Fallon/Getty Images)
🔥🔥🔥🔥🔥🔥🔥🔥

Rivian finally made a gross profit, but the company is still a cash incinerator extraordinaire

Rivian’s stunning adventure vehicles don’t burn anything to keep moving. That’s not true for the company itself.

David Crowther

Yesterday, electric vehicle manufacturer Rivian reported a major milestone: $170 million of gross profit in Q4, the company’s first-ever quarter with that metric out of the red. Investors liked that, but had less sympathy for Rivian’s new delivery guidance of 46,000 to 51,000 vehicles, which at its midpoint implies that the company is expecting to deliver roughly 6% fewer vehicles than the ~51,600 it managed in 2024.

EVaporating

Selling cars for more than they cost you to make is, of course, a major step down the road toward profitability. But covering the rest of your company’s expenses — marketing, sales, research and development, HR, accounting, legal — is a completely different journey. And for Rivian, it’s one that will require a lot more scale... and a lot more capital. Since Rivian’s public markets debut in 2021, when it raised ~$13.5 billion — America’s seventh largest IPO at the time — the company has been steadily burning its cash reserves.

Rivian Cash
Sherwood News

While the company’s cash pile actually rose this quarter by about $1 billion, that figure was lifted thanks to $1.3 billion received in November in conjunction with the closing of its joint venture with automotive giant Volkswagen. For the year as a whole, the company still burned through $1.7 billion in its core operating activities.

On the earnings call, Claire Rauh McDonough, the company’s chief financial officer, addressed the issue:

During 2024, we reinforced Rivians long-term financial flexibility. We received $2.3 billion of the expected $5.8 billion of funding from the joint venture transaction with Volkswagen Group. We also announced the closing of an up to $6.6 billion Department of Energy loan, which together with the remaining proceeds from the Volkswagen Group is expected to fund an incremental $10.1 billion of potential capital on top of the $7.7 billion of capital we had on hand as of December 31, 2024.

TLDR: Rivian says it has nearly $18 billion of accessible capital on hand to ramp up the production of its R2 and R3 vehicles and forge a path toward actually making money. A few short years ago, it had a very similar amount on its balance sheet.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.